1. Scrip

Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition

May Commercialize Therapy Alone

 
• By Ayisha Sharma

The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.    

Start track. Lanes 1, number one of a red racing track.
The US Nod Marks Boehringer's First Major New Drug Approval In Years • Source: Shutterstock

Boehringer Ingelheim GmbH’s spesolimab is the first drug approved for generalized pustular psoriasis (GPP) flares but the niche indication could present challenges surrounding diagnosis and awareness.

The private firm will market spesolimab under the brand name Spevigo following a thumbs-up from the US Food and Drug Administration based

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.